{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-043362","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.523656+00:00","generated_at":"2026-05-21T08:29:42.941922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Citius Pharma Q2 net loss $11.5M; cash only $26K; needs capital beyond May 2025","bullets":["Net loss of $11.5M ($1.27 per share) for Q2 fiscal 2025 vs $8.5M a year ago.","Cash and cash equivalents only $26,410 as of March 31, 2025.","Company will need additional capital to support operations beyond May 2025.","R&D expenses $3.8M; G&A expenses $4.8M, both up vs prior year.","Plans to secure financing for LYMPHIR launch; retained Jefferies for strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-043362","json":"https://secwatch.observer/filing/0001213900-25-043362.json","markdown":"https://secwatch.observer/filing/0001213900-25-043362.md","text":"https://secwatch.observer/filing/0001213900-25-043362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025043362/0001213900-25-043362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025043362/ea0241974-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:29:42.941922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}